|
|
|
| Different Influences Between Long-term Treated IGF-Ⅰand MGF About Glycometabolism in Mice |
| LI Chuan-bao1,2, HUA Tian2, DU Hong-wu1,2 |
1. Research Center for Bioengineering & Sensing Technology Department of Biotechnology, Beijing 100083, China;
2. University of Science and Technology Beijing, Beijing 100083, China |
|
|
|
Abstract To investigate the long term effect of glucose metabolism in gene therapy by using IGF-Ⅰ and MGF, the MGF and IGF-Ⅰ eukaryotic expression vector were constructed, and then imported into the left quadriceps of mice every 2 weeks. The sugar tolerance of these mice was tested at the 15th week after the first injection by Yicheng blood glucose meter (JPS-5). It was found that the balance of glucose tolerance was broken when IGF-Ⅰ gene were injected into mice, the blood glucose could reach 12.07 ± 1.35mmol / L, which is significantly higher than the control group (10.15±0.87mmol/L) and the MGF group (10.58 ± 0.61mmol/L). At the same time, the combine injection of both MGF and IGF-Ⅰcould significant reduce the ability of regulating blood sugar, the value (16.30 ± 2.69mmol / L) was rank highest in all of the tested group (P <0.001). Long-term presence of IGF-Ⅰ may antagonize insulin in vivo and then reduce the ability of glycometabolism, however, MGF does not show this function. Integrating the results of combination with IGF-Ⅰand MGF, the speculation that IGF-Ⅰantagonize to insulin mainly through its N-terminal, and its C-terminal which exposed do the formation and function of glucose metabolism could be made, or MGF promotes muscle cell to absorb and express exogenous DNA, which can be used as an adjuvant of gene vaccine.
|
|
Received: 30 November 2011
Published: 25 April 2012
|
|
|
|
|
|
[1] Daughaday W H, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev, 1989, 10 (1):68-91.
[2] Froesch E R, Muller W A, Burgi H, et al. Non-suppressible insulin-like activity of human serum. II. Biological properties of plasma extracts with non-suppressible insulin-like activity. Biochim Biophys Acta, 1966, 121 (2):360-374.
[3] Froesch E, Buergi H, Ramseier E, et al. Antibody-suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance. J Clin Invest, 1963, 42:1816-1834.
[4] Le R D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med, 1997, 336 (9):633-640.
[5] Rinderknecht E, Humbel R E. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem, 1978, 253 (8):2769-2776.
[6] Russell-Jones D L, Bates A T, Umpleby A M, et al. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest, 1995, 25 (6):403-411.
[7] Boulware S D, Tamborlane W V, Rennert N J, et al. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest, 1994, 93 (3):1131-1139.
[8] Moses A C, Young S C, Morrow L A, et al. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes, 1996, 45 (1):91-100.
[9] Morrow L A, O’Brien M B, Moller D E, et al. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab, 1994, 79 (1):205-210.
[10] Jabri N, Schalch D S, Schwartz S L, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes, 1994, 43 (3):369-374.
[11] Zenobi P D, Jaeggi-Groisman S E, Riesen W F, et al. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest, 1992, 90 (6):2234-2241.
[12] Carroll P V, Christ E R, Umpleby A M, et al. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes, 2000, 49 (5):789-796.
[13] Frystyk J, Skjaerbaek C, Vestbo E, et al. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev, 1999, 15 (5):314-322.
[14] Cannata D, Fierz Y, Vijayakumar A, et al. Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med, 2010, 77 (2):197-213.
[15] Rajpathak S N, Gunter M J, Wylie-Rosett J, et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev, 2009, 25 (1):3-12.
[16] Ranke M B. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab, 2005, 16 (4):190-197.
[17] Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J Physiol, 2003, 549 (Pt 2):409-418.
[18] Hameed M, Orrell R W, Cobbold M, et al. Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol, 2003, 547 (Pt 1):247-254.
[19] Aperghis M, Johnson I P, Cannon J, et al. Different levels of neuroprotection by two insulin-like growth factor-I splice variants. Brain Res, 2004, 1009 (1-2):213-218.
[20] Dluzniewska J, Sarnowska A, Beresewicz M, et al. A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia. Faseb J, 2005, 19 (13):1896-1898.
[21] Goldspink G. Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping. Br J Sports Med, 2005, 39 (11):787-788, 787-788.
[22] Hirsch T, Spielmann M, Velander P, et al. Insulin-like growth factor-1 gene therapy and cell transplantation in diabetic wounds. J Gene Med, 2008, 10 (11):1247-1252.
[23] Leme J A, Silveira R F, Gomes R J, et al. Long-term physical training increases liver IGF-I in diabetic rats. Growth Horm Igf Res, 2009, 19 (3):262-266.
[24] Brismar K, Fernqvist-Forbes E, Wahren J, et al. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab, 1994, 79 (3):872-878.
[25] Migdalis I N, Kalogeropoulou K, Kalantzis L, et al. Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy. Diabet Med, 1995, 12 (9):823-827.
[26] Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda), 2005, 20(4):232-238.
[27] Yang S Y, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. Febs Lett, 2002, 522 (1-3):156-160.
[28] Mills P, Lafreniere J F, Benabdallah B F, et al. A new pro-migratory activity on human myogenic precursor cells for a synthetic peptide within the E domain of the mechano growth factor. Exp Cell Res, 2007, 313 (3):527-537.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
